| Literature DB >> 28962484 |
Ansoumane Kourouma1, Hady Keita2, Peng Duan1, Chao Quan1, Koikoi Kebe Bilivogui3, Suqin Qi1, Ndjiembi Adjonga Christiane4, Aidogie Osamuyimen4, Kedi Yang1.
Abstract
An emerging literature suggests that early life exposure to 4-nonylphenol (4-NP), a widespread endocrine disrupting chemical, may increase the risk of metabolic syndrome. In this study, we investigated the hypothesis that intraperitoneal administration of 4-NP induces hepatic steatosis in rat. 24 male Sprague-Dawley rats were administered with 4-NP (0, 2, 10 and 50 mg/kg b.wt) in corn oil for 30 days. Liver histology, biochemical analysis and gene expression profiling were examined. After treatment, abnormal liver morphology and function were observed in the 4-NP-treated rat, and significant changes in gene expression an indicator of hepatic steatosis and apoptosis were observed compared with controls. Up-regulated genes involved in apoptosis, hepatotoxity and oxidative stress, increased ROS and decrease of antioxidant enzyme were observed in the 4-NP exposed rat. Extensive fatty accumulation in liver section and elevated serum GOT, GPT, LDH and γ-GT were also observed. Incidence and severity of liver steatosis was scored and taken into consideration (steatosis, ballooning and lobular inflammation). Hepatocytes apoptosis could promote NAFLD progression; Fas/FasL, TNF-α and Caspase-9 mRNA activation were important contributing factors to hepatic steatosis. These findings provide the first evidence that 4-NP affects the gene expression related to liver hepatotoxicity, which is correlated with hepatic steatosis.Entities:
Keywords: 4-NP, 4-nonylphenol; 4-Nonylphenol; 4-Nonylphenol (PubChem CID: 1752); APNEIs, alkylphenol polyethoxylates; AhR, aril hydrocarbon receptor; Apoptosis; Aprotinin (PubChem CID: 22833874); Bouin's fluid (PubChem CID: 124013); Collagenase (PubChem CID: 5046512); Cyt c, cytochrome c; Diamninobenzidine Tetrahydrochloride (PubChem CID: 23892); FAO, fatty acid oxidation; FFA, free fatty acid; GOT, glutamic-oxalacetic transaminase; GPT, glutamate pyruvate transaminase; Genes; HSC, hepatic stellate cell; Hematoxylin Eosin (PubChem CID: 86598188); Hepatic steatosis; Hydrogen peroxide (PubChem CID: 784); IR, insulin resistance; LDH, lactate dehydrogenase; Liver; Malondialdehyde (PubChem CID: 10964); NAFLD, nonalcoholic fatty liver disease; NASH, non-alcoholic hepatic steatosis; Nitrotetrazolium Blue chloride (PubChem CID: 9281); OS, oxidative stress; Oxidative stress; PPAR, peroxisome proliferation-activated receptor; Phenylmethylsulfonyl fluoride (PubChem CID: 4784); ROS, reactive oxygen species; Sodium chloride (PubChem CID: 5234); Superoxide (PubChem CID: 5359597); TAG, triacylglycerol; Thiobarbituric Acid (PubChem CID: 2723628); Trizol (PubChem CID: 378478); Tromethamine (Tris) (PubChem CID: 6503); Xylene (PubChem CID: 6850715); γ-GT, gamma glutamyltransferase
Year: 2015 PMID: 28962484 PMCID: PMC5598540 DOI: 10.1016/j.toxrep.2015.10.006
Source DB: PubMed Journal: Toxicol Rep ISSN: 2214-7500
Grading and staging of histopathological of liver steatosis.
| Grade | Histological characteristics |
|---|---|
| 1-Mild | Steatosis: predominantly macrovesicular |
| Ballooning: occasionally observed | |
| Lobular inflammation: scattered and mild acute inflammation | |
| 2-Moderate | Steatosis: any degree usually mixed macrovesicular and microvesicula |
| Ballooning: obvious and present in centrilobular zone | |
| Lobular inflammation: associated with ballooned hepatocytes | |
| 3-Severe | Steatosis: typically involves >66% of lobules |
| Ballooning: predominantly, marked in centrilobular zone | |
| Lobular inflammation: scattered acute and chronic inflammation |
According to Brunt et al. grading and staging system for NASH [7].
Body weight (g) and selected absolute (g) and relative organ weight (mg/g) of male rats in control and treatment groups. Doses of 4-NP (mg/kg b.wt.).
| Initial body weight (g) | Final body weight (g) | Liver weight | ||
|---|---|---|---|---|
| Absolute (g) | Relative-to-body (mg) | |||
| Control | 78.93 ± 5.96 | 246.63 ± 14.89 | 7.63 ± 1.54 | 30.82 ± 5.27 |
| 2 mg | 75.25 ± 4.72 | 243.40 ± 11.76 | 7.94 ± 1.13 | 32.72 ± 5.08 |
| 10 mg | 73.37 ± 6.61 | 260.30 ± 16.63 | 9.23 ± 0.78 | 35.69 ± 4.20 |
| 50 mg | 76.33 ± 5.97 | 267.91 ± 14.91 | 9.44 ± 0.67 | 35.26 ± 2.54 |
Values are expressed as mean ± SD, n = 6. The symbol represents statistical significant (ANOVA) from control.
p < 0.05.
Fig. 1Effect of 4-NP on liver biomarkers. (A) Effect of 4-NP on GOT activities (U/g of protein) in the liver of rats. (B) Effect of 4-NP on GPT activities (U/g of protein) in the liver of rats. (C) Effect of 4-NP on LDH activities in (U/mg of protein) the liver of rats. (D) Effect of 4-NP on γ-GT activities (U/mg of protein) in the liver of rats. Values are expressed as mean ± SD, n = 6. The symbol represents statistical significant (ANOVA) from control: *p < 0.05, **p < 0.01, ***p < 0.001.
Effect of 4-NP on liver oxidative stress and antioxidant enzyme activity in all experimental groups. Doses of 4-NP (mg/kg b.wt.).
| CAT (U/mg prot) | GSH-P | SOD (U/mg prot) | H2O2 (μmol/mg prot) | MDA (nmol/mg prot) | |
|---|---|---|---|---|---|
| Control | 14.045 ± 2.08 | 1.932 ± 0.15 | 14.502 ± 2.79 | 2.045 ± 0.41 | 1.461 ± 0.49 |
| 2 mg | 10.23 ± 1.91 | 1.280 ± 0.45 | 14.156 ± 2.18 | 2.428 ± 1.00 | 1.881 ± 0.55 |
| 10 mg | 5.833 ± 2.67 | 0.632 ± 0.39 | 12.359 ± 1.82 | 2.451 ± 0.28 | 3.013 ± 0.46 |
| 50 mg | 4.318 ± 2.28 | 0.471 ± 0.29 | 10.414 ± 2.20 | 3.066 ± 0.47 | 3.199 ± 0.81 |
Effect of 4-NP on liver antioxidant enzymes and reactive oxygen species. Values are expressed as mean ± SD, n = 6. The symbol represents statistical significant (ANOVA) from control.
p < 0.05.
p < 0.01.
p < 0.001.
Fig. 2Effects of 4-NP (mg/k b. wt) on oxidative stress-related genes expression of experimental rat livers ((A) SOD1, (B) GPx, (C) HSP70). Apoptotic-related genes ((D) Bax, (E) Bcl-2, (F) Casp-9). Hepatotoxicity-related genes ((G) Fas, (H) FasL, (I) TNF-α). The housekeeping gene β-actin is used as an internal positive control. The relative expression of target genes is calculated using 2−ΔΔCt. Error bars represent the standard deviation. Significant difference:*p < 0.05, **p < 0.01 versus control group. n = 6.
Fig. 3Hepatic histology of rats livers sections, showing cellular changes, particularly vacuoles (arrows), indicating steatosis. (D) Show several balloon cells that are much larger than the surrounding steatotic hepatocytes but with the same cytoplasmic characteristic as more obvious balloons, such as those seen in (B and C). Observations done at 200× magnification (H&E). (E) Grading for steatohepatitis, three grades are summarized (steatosis, ballooning and lobular inflammation).
Fig. 4Detection of apoptosis TUNEL assay in the liver tissue of rats. The presence of apoptosis after treatment with (2, 10 and 50 mg/kg/ b.wt) of 4-NP by intraperitoneal injection for 30 days. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
(B–D) DNA fragmentation, characteristic of apoptosis (blacks arrows), (red arrows) indicates ballooning. (E) The graph representing average number of TUNEL-positive cells in each group). Observations done at 200× magnification. Apoptotic index of liver (%). The tissue sections were counted for each rat. The symbol represents statistical significant (ANOVA) from control: *p < 0.05, **p < 0.01, ***p < 0.001.
Fig. 54-NP promotes hepatic cell proliferation in acute liver injury. Immunohistochemical staining for proliferating cell nuclear antigen (PCNA) was carried out as previously described. (A) PCNA staining liver sections in the rats without 4-NP administration. (B–D) Low middle and high dose respectively, arrows indicate PCNA+ cells in the liver sections. (E) Quantitative expression of PCNA was significantly higher in the liver cells at dose 10 and 50 mg/kg b. wt. The graph representing average number of PCNA+ cells in each group. Observations done at 200× magnification. PCNA+ index of liver (%). The tissue sections were counted for each rat. The symbol represents statistical significant (ANOVA) from control: *p < 0.05, **p < 0.01, ***p < 0.001.